Latest Headlines

Latest Headlines

Abbott strikes companion Dx deal with AstraZeneca for severe asthma therapy

Abbott is teaming up with biotech heavyweight AstraZeneca to develop companion diagnostic tests for the company's investigational asthma therapy, a potentially fruitful alliance as Abbott rides the tailwinds of promising diagnostic sales.

Is there a place for pharma in the emerging EHR market?

More than three-fourths of practices have implemented a basic electronic health record system, according to HHS numbers, and around half now use advanced versions. EHR software vendors have direct access to--and the undivided attention of--those healthcare providers in a whole new way.

FibroGen gets $15M from AZ as it advances roxadustat candidate toward China nod

AstraZeneca paid a $15 million milestone payment to U.S.-based FibroGen as it works on moving to file for China FDA approval for roxadustat, an anemia candidate in clinical trials, as early as next year.

Big Pharma's cardiovascular sales ain't what they used to be

Slumping sales for cardiovascular drugs isn't exactly a new phenomenon for Big Pharma, with some of the industry's top drugmakers suffering from recent patent expirations. But a new report shows which CV franchises have been hurt the most. 

Flagship's startup factory recruits AstraZeneca, Bayer and Nestlé

Doubling down on its in-house startup academy, biotech VC stalwart Flagship Ventures has recruited a trio of big-name corporate sponsors to lend their expertise to its next class of seedlings, expanding its focus well beyond traditional drug development.

Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spend

It's a good thing for Medicare that AstraZeneca's Nexium has gone generic and Teva's Copaxone is headed that way. That is because they are among about 10% of the drugs covered by Medicare which account for about 25% of the cost.

From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1 (Part 2)

FiercePharmaAsia  combs earnings calls by major drug companies for notable and quotable nuggets on emerging markets and Asia to track the latest sales trends and insight into business outlooks in markets as diverse as China, India and Japan to Southeast Asia.

AstraZeneca scores fast-track FDA review for big new Brilinta use

Analysts weren't as excited about new Brilinta outcomes data as AstraZeneca was. The company is eyeing $3 billion in peak sales for the clot-buster, partly with the help of the PEGASUS trial, unveiled last month. Analysts figure on half that.

AstraZeneca's Brilinta gets into the FDA's fast lane for new use

AstraZeneca's clot-fighter Brilinta got a lift from the FDA Wednesday, as the agency said it would fast-track review of the drug for broader use. The drugmaker could get an OK in the third quarter, for use in heart attack patients up to three years after the event.

Merck could be in for big Januvia boost, thanks to 'completely balanced' heart data

In one quick announcement Monday, Merck's diabetes drug Januvia became the drug to beat in its class. New study data could boost Januvia's sales by 10% in 2020.